TGFB1 and endometrial cancer: Since TGFBR2 is partially silencing mutated in Ishikawa and Ishikawa-02 cells, instead of adopting short-term TGF-β treatment for 24 hours used in the conventional invasion assay, we measured long-term TGF-β effect for 10 days on endometrial cancer cell growth and SOX2 expression.